Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Rapid Impact Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Metabolism Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Spotlight on Genomic Analysis of Rare and Understudied Cancers
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Research
Molecular Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Rapid Impact Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Metabolism Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Spotlight on Genomic Analysis of Rare and Understudied Cancers
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Signaling and Regulation

The Essential Role of Giα2 in Prostate Cancer Cell Migration

Miao Zhong, Shineka Clarke, BaoHan T. Vo and Shafiq A. Khan
Miao Zhong
Center for Cancer Research and Therapeutic Development, Clark Atlanta University, Atlanta, Georgia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shineka Clarke
Center for Cancer Research and Therapeutic Development, Clark Atlanta University, Atlanta, Georgia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
BaoHan T. Vo
Center for Cancer Research and Therapeutic Development, Clark Atlanta University, Atlanta, Georgia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shafiq A. Khan
Center for Cancer Research and Therapeutic Development, Clark Atlanta University, Atlanta, Georgia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1541-7786.MCR-12-0219 Published October 2012
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Cell- and receptor-specific regulation of cell migration by Gi/oα-proteins remains unknown in prostate cancer cells. In the present study, oxytocin (OXT) receptor was detected at the protein level in total cell lysates from C81 (an androgen-independent subline of LNCaP), DU145 and PC3 prostate cancer cells, but not in immortalized normal prostate luminal epithelial cells (RWPE1), and OXT-induced migration of PC3 cells. This effect of OXT has been shown to be mediated by Gi/oα-dependent signaling. Accordingly, OXT inhibited forskolin-induced luciferase activity in PC3 cells that were transfected with a luciferase reporter for cyclic AMP activity. Although mRNAs for all three Giα isoforms were present in PC3 cells, Giα2 was the most abundant isoform that was detected at the protein level. Pertussis toxin (PTx) inhibited the OXT-induced migration of PC3 cells. Ectopic expression of the PTx-resistant Giα2-C352G, but not wild-type Giα2, abolished this effect of PTx on OXT-induced cell migration. The Giα2-targeting siRNA was shown to specifically reduce Giα2 mRNA and protein in prostate cancer cells. The Giα2-targeting siRNA eliminated OXT-induced migration of PC3 cells. These data suggest that Giα2 plays an important role in the effects of OXT on PC3 cell migration. The Giα2-targeting siRNA also inhibited EGF-induced migration of PC3 and DU145 cells. Expression of the siRNA-resistant Giα2, but not wild type Giα2, restored the effects of EGF in PC3 cells transfected with the Giα2-targeting siRNA. In conclusion, Giα2 plays an essential role in OXT and EGF signaling to induce prostate cancer cell migration. Mol Cancer Res; 10(10); 1380–8. ©2012 AACR.

Introduction

Heterotrimeric guanosine phosphate-binding proteins (G-proteins) are composed of α, β, and γ subunits. Gβ and Gγ form a dimer that is associated with inactive Gα (1–3). Activated G-protein–coupled receptor (GPCR) catalyzes the exchange of guanosine diphosphate for GTP on Gα, resulting in the dissociation of Gβγ from the activated Gα (4). Gα subunits have intrinsic GTPase activities that hydrolyze the GTP into GDP and terminate the G-protein-coupled signaling (4). The GTP hydrolysis is accelerated by the regulator of G-protein signaling protein (RGS; ref. 4). There are 23 Gα isoforms that are divided into 4 subfamilies, including Gs, Gi/o, Gq/11, and G12/13 (4). Activation of Gi/o-proteins inhibits adenylyl cyclases and reduces intracellular cyclic AMP (cAMP) levels (5). Giα1, Giα2, Giα3, GoαA, and GoαB are Gi/oα-proteins that are ubiquitously expressed and sensitive to pertussis toxin (PTx; ref. 4). GoαA and GoαB are derived from splice variants of the Goα gene that is preferentially expressed in the central nervous system (6, 7). PTx catalyzes ADP ribosylation of the cystine (C) residues at C-terminal ends of the Gi/oα-proteins, which results in the uncoupling of these G-proteins from their cognate GPCRs (8). Substitution of the cystine for glycine eliminates the PTx ADP-ribosylation site, however, the resulting Gi/oα mutants have been shown to retain abilities to couple to GPCRs and induce biologic responses (9).

Prostate cancer development and progression is androgen dependent, and androgen deprivation therapy is currently among the regular procedures to treat metastatic prostate cancer (10–12). However, disease relapse often ensues from androgen ablation, producing castration resistant prostate cancer that results in increased malignancy and poor prognosis (10, 12, 13). Emerging evidence has suggested that GPCR signaling plays an important role in prostate cancer progression (14). Activation of G12/13-proteins has been shown to increase prostate cancer invasion via activation of RhoA family of small G-proteins (15). Both Gs- and Gq-dependent signaling induce the transactivation of androgen receptor in prostate cancer cells (16, 17), which has been shown to facilitate transition of primary prostate tumor cells to the androgen-independent stage (18). Expression of RGS2, a negative regulator of Gi- as well as Gq-dependent signaling, is significantly reduced in human prostate cancer specimens when compared with the adjacent normal or hyperplastic prostate tissues (19). Therefore, signaling of GPCRs, either Gi or Gq coupled, is potentially amplified in primary prostate tumors. PTx has been shown to inhibit the growth of PC3 prostate cancer cells (20). PTx sensitivity indicates the involvement of Gi/o-dependent signaling (8). Nevertheless, PTx treatment cannot distinguish receptor- and cell-specific functions of Gi/oα isoforms. Activated CXCR3 receptor induces migration of T lymphocytes via a Giα2-dependent mechanism, which is counteracted by Giα3 (21). There is no evidence suggesting the presence of isoform-specific functions of heterotrimeric G-proteins in prostate cancer cells.

Oxytocin (OXT) is a peptide hormone that regulates normal prostate functions. OXT treatment has been shown to increase epithelial cell growth, 5α-reductase activity, and contractility in normal prostate (22–24). However, the information is very limited about the effect of OXT on prostate cancer progression. OXT receptor (OXTR) has been detected in tissues from hyperplastic and neoplastic prostate (25), but not in the epithelium of normal human prostate (26). Recently, OXTR has been shown to be the primary target of OXT in androgen-independent prostate cancer cell lines (DU145 and PC3; ref. 27). OXTR is a GPCR that promiscuously couples to multiple G-proteins including Gq and Gi (28, 29). Activated OXTR induces migration of PC3 cells via a PTx-sensitive mechanism (27). In the present study, OXTR protein was detected in prostate cancer cell lines (C81, DU145, and PC3), but not in the normal prostate epithelial cell line (RWPE1). Furthermore, we investigated whether specific Gi/oα isoforms were required for the migration of PC3 cells. Giα2 was the most abundant isoform of the Gi/oα family members that was detected at the protein level and this isoform was found to play an essential role in prostate cancer cell migration.

Materials and Methods

Reagents

Human OXT, pertussis toxin, bovine serum albumin (BSA), rabbit anti-OXTR antibody, anti-α-tubulin antibody, and mouse anti-β-actin antibody were obtained from Sigma. Mouse monoclonal anti-Giα1 antibody, rabbit anti-Giα2, and anti-Giα3 antibodies were obtained from EMD-Millipore Total lysates from Escherichia coli expressing recombinant rat Giα1, Giα2, and Giα3 proteins and an additional rabbit anti-human Giα2 antibody, were purchased from Santa Cruz Biotechnology. Steady glow luciferase reagent, Moloney murine leukemia virus reverse transcriptase, T4-ligase, GoTaq qPCR master mix, and oligo dT primer were purchased from Promega. Taq polymerase was purchased from Lucigen. Phusion high-fidelity PCR kit and restriction enzymes were purchased from New England Biolabs. DNA primers were purchased from IDT. EGF, Trizol, lipofectamine 2000, control and Giα2-targeting (siRNA ID#: s5875, Ambion) siRNAs were purchased from Life Technology. TransIt-TKO transfection reagent was obtained from Mirus. Rat-tail collagen and transwell inserts were obtained from BD Biosciences. Cell culture reagents and G418 sulfate were purchased from Mediatech Inc.

Plasmids

Human Giα2 and the Giα2-C352G mutant in pcDNA3.1 (Life Technology) were obtained from Missouri S&T cDNA Resource Center. The siRNA-resistant Giα2 gene was created by modification of the Giα2 siRNA-targeting sequence without any change in the protein sequence. The modified sequence was generated by PCR and ligated into the Giα2 gene after digestion with Kpn I and BamH I restriction enzymes. Sequences of the 2 sets of PCR primers were, Forward 1: GCT TGG TAC CAC CAT GGG CTG; Reverse 1: GTG TTC GAA TAC ACT ACG GCT CGG TAC TGC CGG CAT TCC TCC TC, Forward 2: TAC CGA GCC GTA GTG TAT TCG AAC ACC ATC CAG TCC ATC ATG GC; Reverse 2: GCA GTG GAT CCA CTT CTT CCG CT. The siRNA-resistant Giα2 clone was verified by DNA sequencing. The pADneo2 C6-BGL plasmid containing luciferase reporter for cAMP was a gift from Dr. Tu-Yi (Creighton University, Omaha, NE).

Cell culture

Immortalized prostate luminal epithelial cell line (RWPE1), DU145, and PC3 prostate cancer cell lines were obtained from American Type Culture Collection (Rockville, MD). Androgen-independent LNCaP subline C81 was kindly provided by Dr. Ming-Fong Lin (University of Nebraska, Omaha, NE). Immortalized pregnant human myometrial smooth muscle cells (PHM1-41) were a gift from Dr. Barbara Sanborn (Colorado State University, Fort Collins, CO). RWPE1 cells were maintained in keratinocyte growth medium (Invitrogen). The C81 cell lines were maintained in RPMI-1640 supplemented with 250 μg/mL gentamycin and 10% FBS. DU145 and PC3 cells were maintained in Minimum Essential Media supplemented with 5% FBS. PHM1-41 cells were maintained in Dulbecco's Modified Eagle's Media supplemented with 10% FBS.

Transfection of siRNAs

DU145 and PC3 cells were seeded in 6-well plates at a density of 1.5 × 105 cells per well. The next day, cells were transfected with control siRNA or the Giα2-targeting siRNA using the TransIT-TKO transfection reagent. Briefly, Minimum Essential Media (200 μL/well) containing 30 nmol/L of siRNA was mixed with the transfection reagent (8 μL/well) and incubated for 20 minutes. siRNA mixtures were added drop by drop into 6-well plates. The transfection media were replaced with the regular culture media (2 mL/well) the next day. RNA samples were harvested 72 hours after transfection. Protein samples were collected at 72 and 96 hours after transfection.

Transfection of plasmid DNAs

Minimum Essential Media (200 μL/well) containing plasmid DNA (2 μg/well) was mixed with lipofectamine 2000 (6 μL/well) and incubated for 30 minutes. Plasmid DNA mixtures were added drop by drop into 6-well plates. Transfected PC3 cells were cultured for up to 48 hours.

Generation of PC3 cell lines ectopically expressing wild-type and the siRNA-resistant Giα2

Transfected PC3 cells were placed in 100 mm2 culture dishes and were grown in culture medium supplemented with 600 μg/ml of G418. A week later, cells were maintained in culture medium supplemented with 200 μg/ml of G418. Single colonies were picked and grown in 6-well plates. Expression of Giα2 was verified in total cell lysates by Western blot analysis.

Western blot analysis

PC3 cell membranes were prepared as described previously (30). Membrane proteins (50 μg) or total cell proteins (100 μg) were separated on 10% SDS-PAGE gels and transferred onto polyvinylidene difluoride (PVDF) membranes and analyzed for Western blotting as described previously (27). Giα1-3 proteins were detected with isoform-specific antibodies (1:1,000 dilution). OXTR was detected in total cell lysates with anti-OXTR antibody (1:1,000 dilution). Thirty microgram of total cell proteins were used for detection of β-actin with a mouse monoclonal antibody (1:10,000 dilution). The signal was detected by ECL (Thermo Scientific).

RNA extraction, reverse transcription-PCR and quantitative real-time PCR

Total RNAs were extracted from cells using Trizol and the RNA content was determined at 260 nm with a UV spectrophotometer. First strand cDNA was synthesized from 2 μg of total RNA as described previously (27). No reverse transcriptase (RT) control samples were prepared in parallel by replacing reverse transcriptase with RNase.

Expression of Giα1, Giα2, Giα3, GoαA, GoαB, and L19 genes was detected with the PCR procedure described previously (27). Specific primers are listed in Table 1. PCR products were separated by electrophoresis on 1.5% agarose gels containing ethidium bromide. DNA bands were visualized under UV light and images were documented using the Bio-Rad gel imager.

View this table:
  • View inline
  • View popup
Table 1.

RT-PCR and quantitative PCR primers

For quantitative real-time PCR, cDNA samples (1 μL) were mixed with 0.2 μmol/L primers and 2X GoTaq qPCR master mix in a final volume of 25 μL in a 96-well PCR plate. PCR detection was conducted in an iCycler thermal cycler (Bio-Rad) with procedures described previously (27). Melting curves were examined for the quality of PCR amplification of each sample. Calculations were conducted using the ΔΔCt method (27).

Cloning Giα1 and Giα3 genes from PC3 and DU145 cell lines

Open reading frames of Giα1 and Giα3 genes were amplified with the Phusion high-fidelity PCR kit. The shared forward primer was, GCT TGG TAC CAT GGG CTG CAC GTT GAG CGC C. The reverse primer for Giα1 was, TAG ACT CGA GAT GCA TTT TAC CAT GAA CTG CAA. The reverse primer for Giα3 was, GCT TGG TAC CAT GGG CTG CAC GTT GAG CGC C. The PCR procedure was programmed as following: 94°C for 2 minutes, 30 cycles of the following steps: denaturation at 94°C for 30 seconds, annealing at 60°C for 20 seconds, and extension at 72°C for 1 minute. A final extension of 10 minutes was followed up after the cycles were completed. Purified PCR products were digested with Kpn I and Xho I and ligated into pcDNA3.1 plasmid. After transformation into XL1-Blue competent cells (Stratagene), five E. coli colonies containing Giα1- or Giα3-expressing plasmid were grown overnight in LB broth supplemented with ampicillin. Plasmids were harvested with QIAprep spin miniprep kit (Qiagen) and sequenced from both ends with the cloning primers.

Luciferase reporter assay

The PC3 cells were harvested from the 6-well plates 24 hours after transfection with the pADneo2 C6-BGL plasmid. Aliquots of 30,000 cells were placed in an opaque 96-well plate for different treatments, including control, forskolin (5 μmol/L) and forskolin plus different concentrations of OXT. After treatment for 5 hours, 100 μL of steady-glow luciferase detection reagent was added to each well of the 96-well plate. The luciferase activities were detected with OPTIMA LUMIstar plate reader (BMG LABTECH, NC). The results are expressed as percentile of the forskolin-stimulated luciferase activity.

Cell migration assay

In vitro cell migration assay was conducted using 24-well transwell inserts (8 μm) as described previously (27). Briefly, cells were harvested and centrifuged at 500 g for 10 minutes at room temperature. The pellets were resuspended into Minimum Essential Media supplemented with 0.2% BSA at a cell density of 3 × 105 cells/mL. Transwell inserts were treated with rat-tail collagen (50 μg/mL) as described previously (27). Chemoattractant solutions were made by diluting OXT (100 nmol/L) or EGF (3 ng/mL) into Minimum Essential Media supplemented with 0.2% BSA. Minimum Essential Media containing 0.2% BSA served as a control medium. Aliquots of 100 μL cell suspension were loaded into transwell inserts and placed into 24-well plates that contained control and chemoattractant solutions (300 μL/well). The plates were incubated at 37°C for 5 hours. Cells inside the transwell inserts were removed by cotton swabs. The cleaned inserts were fixed in 4% paraformaldehyde (pH 7.5). Cells on the outside of the transwell insert membranes were stained using HEMA 3 staining kit (Fisher Scientific Inc). The number of stained cells was counted as described previously (27). Results were expressed as migration index defined as: the average number of cells per field for test substance/the average number of cells per field for the medium control.

Statistical analysis

Data from multiple independent experiments (n = 3–5) are expressed as mean ± SEM. ANOVA and Duncan's modified multiple range test were used to examine significance between multiple treatments.

Results

OXT activates the Gi/oα-dependent pathway and induces PC3 cell migration

Expression of OXTR is elevated at the mRNA levels in androgen-independent DU145 and PC3 prostate cancer cell lines, compared with normal prostate epithelial cells (27). In the present study, OXTR protein (∼70 kDa) was detected in total cell lysates of DU145, PC3, and the androgen-independent subline of LNCaP (C81) prostate cancer cell lines, but not in the cell lysates of immortalized human prostate luminal epithelial cell line (RWPE1; Fig. 1A). Immortalized pregnant human myometrial smooth muscle cell line (PHM1-41) expresses endogenous OXTR and was used as a positive control (Fig. 1A).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

OXTR receptor expression and functions in human prostate cell lines. A, expression of OXTR was detected with rabbit antibody for OXTR in total cell lysates (50 μg) of RWPE1, DU145, PC3, and C81 cell lines. PHM1-41 expresses endogenous OXTR and was used as a positive control. β-actin was probed on the same blot as sample loading control. B, treatments with OXT and EGF for 5 hours significantly stimulated PC3 cell migration (n = 4). C, twenty-four hours after transfection with the cAMP luciferase reporter (pADneo2 C6-BGL), PC3 cells were pretreated with different concentrations of OXT for 10 minutes before the treatment with forskolin. Luciferase activities were detected 5 hours after treatments and expressed as percentage of the forskolin-stimulated luciferase activity (n = 3). Data were expressed as mean ± SEM and analyzed by ANOVA and Duncan's modified range tests. Significant differences between groups in a given category (P < 0.05) are designated with different lowercase letters.

OXT (100 nmol/L) and EGF (3 ng/mL) induced PC3 cell migration (Fig. 1B). This effect of OXT has been shown to be sensitive to PTx pretreatment, suggesting the involvement of Gi/oα-proteins (27). Inhibiting cAMP accumulation is the canonical function of Gi/oα proteins. PC3 cells were transfected with the pADneo2 C6-BGL plasmid containing a cAMP-responsive luciferase reporter. Forskolin (5 μmol/L) induced a 3-fold increase in luciferase activities in the transfected PC3 cells. Treatment with OXT caused a dose-dependent inhibition of forskolin-stimulated luciferase activity (Fig. 1C), which supports the involvement of Gi/oα in OXTR signaling in PC3 cells.

Giα2 is important for the OXT-induced migration of PC3 cells

Expression of Gi/oα isoforms was detected by RT-PCR with specific primers listed in Table 1. Giα1, Giα2, and Giα3 were the predominant Gi/oα family members that are expressed at the mRNA levels in PC3 cells (data not shown). Because G proteins are enriched in the cell membranes (5), the membrane fractions were prepared from PC3 cells to determine the expression of Giα1-3 proteins. Total lysates (100 ng) of E. coli expressing recombinant rat Giα1-3 proteins were used as positive controls. As shown in Fig. 2A, specific antibodies for Giα1-3 proteins were able to detect respective recombinant proteins. Giα2 was the only Giα family member that was detected in PC3 total cell lysates and membrane fractions (Fig. 2A). In comparison, trace levels of Giα3 protein were detected in only membrane fraction whereas Giα1 was undetectable in both total cell lysates and membrane fractions (Fig. 2A).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Giα2 is potentially important for the OXT-induced migration of PC3 cells. A, total cell lysates and membrane fractions from PC3 cells were separated on 10% SDS-PAGE and transferred onto PVDF membrane. Recombinant rat Giα1-3 were used as positive controls. α-tubulin was detected as a sample loading control for both cell lysates and membranes. Similar results were observed with two separate membrane preparations. B, PC3 cells were treated with PTx (200 ng/mL) 24 hours after transfection with pCDNA3.1, wild type Giα2 and the Giα2-C352G mutant. The next day, transfected PC3 cells were treated with OXT in a transwell migration assay. OXT induced cell migration only in the PC3 cells that were transfected with the Giα2-C352G mutant. Protein levels of Giα2 in cells transfected with empty vector, inGiα2 and the Giα2-C352G mutant in total cell lysates are shown on the top. Data were expressed as mean ± SEM (n = 3) and analyzed by t test (*, P < 0.05).

Mutations causing codon shift might occur in open reading frames of Giα1 and Giα3 genes, which could account for the absence of Giα1 and Giα3 proteins in PC3 cells. Open reading frames of Giα1 and Giα3 genes were cloned by RT-PCR from total RNA samples of PC3 and DU145 cells. DNA sequencing did not identify any mutations in protein coding regions of both genes, indicating that wild-type Giα1 and Giα3 are expressed in DU145 and PC3 cell lines.

Substitution of the C352 for G results in a PTx-resistant Giα2 mutant that retains the ability to transmit signaling of GPCRs (9). PC3 cells were transiently transfected with wild type Giα2 and the Giα2-C352G mutant. Expression of wild-type Giα2 and the Giα2-C352G are shown in Fig. 2B (top). After pretreatment with PTx (200 ng/mL) overnight, OXT (100 nmol/L) treatment induced cell migration only in the PC3 cells that were transfected with the Giα2-C352G mutant (Fig. 2B). These results indicate that activated OXTR couples with Giα2 protein to exert OXT-induced PC3 cell migration.

The endogenous Giα2 is essential for migration of prostate cancer cells

Control and Giα2-targeting siRNAs were transfected into PC3 cells. RNA samples were harvested 72 hours after transfection. Total cell proteins were harvested at 72 and 96 hours after transfection. As shown in Fig. 3A, Giα2 mRNAs were the least abundant among the 3 Giα isoforms in PC3 cell line. Control siRNA did not affect mRNA levels of Giα1-3 in these cells. The Giα2-targeting siRNA specifically reduced Giα2 mRNAs by 96% in this cell line (Fig. 3A). This Giα2-targeting siRNA caused a significant reduction (∼75%) in Giα2 protein levels in PC3 cells at 72 and 96 hours after transfection (Fig. 3B).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Giα2-targeting siRNA specifically silences expression of Giα2 in PC3 cells. A, RNA samples from PC3 cells were harvested 72 hours after transfection with control and Giα2-targeting siRNAs. Giα1-3 mRNA levels were detected with RT-PCR and real-time RT-PCR. No reverse transcriptase (RT) control samples were made by substitution of reverse transcriptase with RNase. Control siRNA did not affect mRNA levels of Giα1-3, the Giα2-targeting siRNA specifically reduced Giα2 mRNAs by 96%. L-19 gene was amplified as a template control. B, total cell lysates from PC3 cells were harvested at 72 and 96 hours after siRNA transfection. β-actin was detected as a sample loading control. Band density was quantified and fold changes over 72 hours control siRNA treatment were calculated. Data were expressed as mean ± SEM (A and B, n = 3) and analyzed by ANOVA and Duncan's modified range tests. C, endogenous Giα2s are important for PC3 cell migration. OXT as well as EGF-induced cell migration in the PC3 cells that were treated with control siRNA. These effects of OXT and EGF were completely eliminated in the PC3 cells that were treated with the Giα2-targeting siRNA. Total cell lysates from PC3 cells were harvested after siRNA transfection followed by Western blot analysis with Giα2 antibody. β-actin was detected as a sample loading control. Data were summarized as mean ± SEM (n = 5) and analyzed by ANOVA and Duncan's modified range tests. Significant differences between groups in a given category (P < 0.05) are designated with different lowercase letters.

OXT and EGF induced cell migration in the PC3 cells that were pretreated with control siRNA (Fig. 3C). On the other hand, these effects of OXT and EGF were completely eliminated in the PC3 cells treated with the Giα2-targeting siRNA (Fig. 3C). Inhibition of EGF-induced cell migration by the Giα2-targeting siRNA was unexpected. To further examine whether Giα2 has a specific role in the EGF-induced cell migration, PC3 stable cell lines were generated to ectopically express wild-type Giα2 and the siRNA-resistant Giα2 genes (Fig. 4A). The Giα2-targeting siRNA completely eliminated EGF-induced cell migration in the PC3 cells that ectopically expresses wild-type Giα2 (Fig. 4A). However, the Giα2-targeting siRNA failed to inhibit effects of EGF on migration of PC3 cells that expressed the siRNA-resistant Giα2 gene (Fig. 4A). These data clearly support a critical role of Giα2 in EGF effects on cell migration. We have previously shown that EGF induces migration of DU145 prostate cancer cells whereas these cells are not responsive to OXT effects on cell migration (27). The Giα2-targeting siRNA, which caused a 93% reduction of Giα2 protein levels, blocked EGF-induced cell migration in DU145 cells (Fig. 4B).

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Endogenous Giα2 plays a specific role in EGF-induced migration of prostate cancer cells. A, expression of Giα2 was detected in total cell lysates from PC3 stable cell lines that ectopically express wild type Giα2 or the siRNA-resistant Giα2 genes. Total cell lysates from these cells were collected after Giα2-targeting siRNA followed by Western blot analysis with Giα2 antibody. β-actin was detected as a sample loading control. The effect of EGF on cell migration was blocked by the Giα2-targeting siRNA in the PC3 cells that ectopically expresses wild-type Giα2. However, this effect of EGF became insensitive to the Giα2-targeting siRNA in the PC3 cell that expresses the siRNA-resistant Giα2. B, The Giα2-targeting siRNA blocked EGF-induced migration of DU145 cells. Total cell lysates from DU145 cells were harvested after siRNA transfection followed by Western blot analysis with Giα2 antibody. β-actin was detected as a sample loading control. Data were expressed as mean ± SEM (A, n = 3. B, n = 4) and analyzed by ANOVA and Duncan's modified range tests. Significant differences between groups in a given category (P < 0.05) are designated with different lowercase letters.

Discussion

OXT is a peptide hormone that regulates normal prostate functions (22–24). However, the information is very limited on the effects of OXT on prostate cancer progression. In the present study, OXTR protein was detected only in prostate cancer cell lines, although OXTR mRNA is expressed in normal and prostate cancer cell lines (27). OXTR was also detected in the PHM1-41 cell lines that express endogenous OXTR (31). These data indicate that expression of OXTR is amplified in prostate cancer cells. Immunohistochemistry staining for OXTR has shown that expression of OXTR is negative in normal human prostate epithelium (26). However, OXTR has been shown to be expressed in hyperplastic as well as neoplastic prostate epithelium and to be increased in the neoplastic tissues when compared with the hyperplastic tissues (25). The expression profile of OXTR in normal and prostate cancer cell lines reflects its expression in human prostate in normal and disease states. Bioinformatic mining of oncomine microarray database (www.oncomine.org) has shown that expression of OXTR is significantly increased in metastatic prostate cancer specimens when compared with normal prostate specimens (32).

OXTR couples to multiple G proteins including Gq and Gi. In turn, these G proteins may convey OXT signaling to different intracellular pathways leading to distinct cellular functions (33). Activated OXTR has been shown to induce migration of PC3 cells (27). This effect of OXT is sensitive to PTx pretreatment, indicating the involvement of Gi/o-dependent signaling (27). Inhibition of the intracellular cAMP accumulation is the canonical function of activated Gi/o proteins (5). By using a luciferase reporter assay to monitor changes in intracellular cAMP levels, we show that OXT caused a dose-dependent inhibition of forskolin-induced luciferase activity. Hence, OXT activates Gi/o-dependent pathways in PC3 cells.

OXTR has been shown to couple to Giα3 in pregnant rat myometrium (29). Nevertheless, there is no evidence that excludes OXTR from coupling to other Gi/oα family members. In fact, OXTR has recently been shown to couple to all of the Gi/oα isoforms in transfected HEK293 cells (34). Expression of Gi/oα isoforms has not been characterized in normal and prostate cancer cell lines. Although Giα1-3 were the predominant Gi/oα family members that were expressed at the mRNA levels in PC3 cells, Giα2 was most abundant isoform which was detected at the protein level in this cell line. Trace amounts of Giα3 protein were detected in the membrane fraction whereas Gia1 protein was completely absent in these cells. This finding cannot be explained by differential regulation of Giα1-3 mRNAs because Giα2 mRNA was expressed at the lowest level among the three Giα isoforms in PC3 cells. Another possibility is that there might be mutations to cause codon shift in the coding regions of Giα1 and Giα3 genes. However, this proved not to be the case because wild-type Giα1 and Giα3 genes were identified in PC3 cells. Therefore, both Giα1 and Giα3 could be diminished in PC3 cells by an unknown posttranscriptional mechanism, which will be studied in the future. In accordance with the present finding, Giα3 protein has been shown to be diminished in primary prostate cancer specimens (35). Ectopic expression of the Giα2-C352G mutant reversed the inhibition by PTx of OXT-induced cell migration in the transfected PC3 cells, suggesting that OXTR couples to Giα2 that may mediate the OXT-induced migration of PC3 cells. To investigate whether the endogenous Giα2 was involved in the OXTR-regulated PC3 cell migration, we used a specific siRNA to silence expression of Giα2 gene. The Giα2-targeting siRNA eliminated the Giα2 mRNA by 96%, but did not alter Giα1 and Giα3 mRNA levels in PC3 cells. A 93% reduction in Giα2 mRNA was also observed in DU145 cells that were treated with the Giα2-targeting siRNA. These data indicate that the Giα2-targeting siRNA is very effective in knocking down expression of Giα2 mRNAs in both PC3 and DU145 cell lines. The Giα2-targeting siRNA significantly blocked the expression of Giα2 protein in PC3 cells, compared with the control siRNA-treated group. Under the validated condition, the Giα2-targeting siRNA completely inhibited the OXT-induced cell migration in PC3 cells. These data indicate that the endogenous Giα2 is required for the OXT-induced migration of PC3 cells. The Giα2-targeting siRNA was also shown to inhibit EGF-induced cell migration in both PC3 and DU145 cell lines. Both Giα1 and Giα3 have been shown to play important roles in EGF-induced cell migration (36, 37). However, our study has provided the first line of evidence supporting a similar role of Giα2 in EGF function. Giα2 plays a specific role, because the Giα2-targeting siRNA was no longer effective to block the EGF-induced cell migration in the PC3 cell line that expresses a siRNA-resistant Giα2 gene. Despite the fact that there is no comprehensive picture about how Giα2 is integrated in the EGF signaling, Giα2 appears to play an essential role in prostate cancer cell migration in response to EGF. Our knockdown studies also indicate that the trace amounts of Giα3 protein are unable to rescue OXT or EGF-induced cell migration in the absence of Giα2 protein.

In summary, the present study has provided direct evidence that support the expression of OXTR in prostate cancer cell lines. OXT treatment has been shown to activate the Gi/oα-dependent signaling. Giα2 is the most abundant member of the Gi/oα family that is detected at the protein level in PC3 cells. Endogenous Giα2 is required for OXT- as well as EGF-induced cell migration in prostate cancer cells. These data suggest that Giα2 plays an essential role in prostate cancer cell migration.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: M. Zhong, B.T. Vo, S.A. Khan

Development of methodology: M. Zhong, B.T. Vo

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): M. Zhong

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): M. Zhong, S. Clarke, B.T. Vo

Writing, review, and/or revision of the manuscript: M. Zhong, B.T. Vo, S.A. Khan

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): M. Zhong, S. Clarke

Study supervision: M. Zhong, S.A. Khan

Grant Support

This work was supported by NIH (RCMI 5G12RR003062 and NIMHD 1P20MD002285-01) and Georgia Research Alliance.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • Received April 9, 2012.
  • Revision received July 24, 2012.
  • Accepted August 15, 2012.
  • ©2012 American Association for Cancer Research.

References

  1. 1.↵
    1. Hamm HE,
    2. Gilchrist A
    . Heterotrimeric G proteins. Curr Opin Cell Biol 1996;8:189–96.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Neer EJ
    . Heterotrimeric G proteins: organizers of transmembrane signals. Cell 1995;80:249–57.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Offermanns S,
    2. Simon MI
    . Organization of transmembrane signalling by heterotrimeric G proteins. Cancer Surv 1996;27:177–98.
    OpenUrlPubMed
  4. 4.↵
    1. Kehrl JH
    . Heterotrimeric G protein signaling: roles in immune function and fine-tuning by RGS proteins. Immunity 1998;8:1–10.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Gilman AG
    . Nobel Lecture. G proteins and regulation of adenylyl cyclase. Biosci Rep 1995;15:65–97.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Huff RM,
    2. Axton JM,
    3. Neer EJ
    . Physical and immunological characterization of a guanine nucleotide-binding protein purified from bovine cerebral cortex. J Biol Chem 1985;260:10864–71.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Sternweis PC,
    2. Robishaw JD
    . Isolation of two proteins with high affinity for guanine nucleotides from membranes of bovine brain. J Biol Chem 1984;259:13806–13.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Kaslow HR,
    2. Burns DL
    . Pertussis toxin and target eukaryotic cells: binding, entry, and activation. Faseb J 1992;6:2684–90.
    OpenUrlAbstract
  9. 9.↵
    1. Senogles SE
    . The D2 dopamine receptor isoforms signal through distinct Gi alpha proteins to inhibit adenylyl cyclase. A study with site-directed mutant Gi alpha proteins. J Biol Chem 1994;269:23120–7.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Tasseff R,
    2. Nayak S,
    3. Salim S,
    4. Kaushik P,
    5. Rizvi N,
    6. Varner JD
    . Analysis of the molecular networks in androgen dependent and independent prostate cancer revealed fragile and robust subsystems. PLoS One 2010;5:e8864.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Shah RB,
    2. Mehra R,
    3. Chinnaiyan AM,
    4. Shen R,
    5. Ghosh D,
    6. Zhou M,
    7. et al.
    Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004;64:9209–16.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Feldman BJ,
    2. Feldman D
    . The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34–45.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Craft N,
    2. Chhor C,
    3. Tran C,
    4. Belldegrun A,
    5. DeKernion J,
    6. Witte ON,
    7. et al.
    Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res 1999;59:5030–6.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Daaka Y
    . G proteins in cancer: the prostate cancer paradigm. Sci STKE 2004;(216):re2.
  15. 15.↵
    1. Kelly P,
    2. Stemmle LN,
    3. Madden JF,
    4. Fields TA,
    5. Daaka Y,
    6. Casey PJ
    . A role for the G12 family of heterotrimeric G proteins in prostate cancer invasion. J Biol Chem 2006;281:26483–90.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Cao X,
    2. Qin J,
    3. Xie Y,
    4. Khan O,
    5. Dowd F,
    6. Scofield M,
    7. et al.
    Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells. Oncogene 2006;25:3719–34.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Kasbohm EA,
    2. Guo R,
    3. Yowell CW,
    4. Bagchi G,
    5. Kelly P,
    6. Arora P,
    7. et al.
    Androgen receptor activation by G(s) signaling in prostate cancer cells. J Biol Chem 2005;280:11583–9.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Terada N,
    2. Shimizu Y,
    3. Kamba T,
    4. Inoue T,
    5. Maeno A,
    6. Kobayashi T,
    7. et al.
    Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model. Cancer Res 2010;70:1606–15.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Wolff DW,
    2. Xie Y,
    3. Deng C,
    4. Gatalica Z,
    5. Yang M,
    6. Wang B,
    7. et al.
    Epigenetic repression of regulator of G-protein signaling 2 promotes androgen-independent prostate cancer cell growth. Int J Cancer 2012;130:1521–31.
    OpenUrlPubMed
  20. 20.↵
    1. Kue PF,
    2. Daaka Y
    . Essential role for G proteins in prostate cancer cell growth and signaling. J Urol 2000;164:2162–7.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Thompson BD,
    2. Jin Y,
    3. Wu KH,
    4. Colvin RA,
    5. Luster AD,
    6. Birnbaumer L,
    7. et al.
    Inhibition of G alpha i2 activation by G alpha i3 in CXCR3-mediated signaling. J Biol Chem 2007;282:9547–55.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Assinder SJ,
    2. Johnson C,
    3. King K,
    4. Nicholson HD
    . Regulation of 5alpha-reductase isoforms by oxytocin in the rat ventral prostate. Endocrinology 2004;145:5767–73.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Bodanszky M,
    2. Sharaf H,
    3. Roy JB,
    4. Said SI
    . Contractile activity of vasotocin, oxytocin, and vasopressin on mammalian prostate. Eur J Pharmacol 1992;216:311–3.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Plecas B,
    2. Popovic A,
    3. Jovovic D,
    4. Hristic M
    . Mitotic activity and cell deletion in ventral prostate epithelium of intact and castrated oxytocin-treated rats. J Endocrinol Invest 1992;15:249–53.
    OpenUrlPubMed
  25. 25.↵
    1. Cassoni P,
    2. Marrocco T,
    3. Sapino A,
    4. Allia E,
    5. Bussolati G
    . Evidence of oxytocin/oxytocin receptor interplay in human prostate gland and carcinomas. Int J Oncol 2004 25:899–904.
    OpenUrlPubMed
  26. 26.↵
    1. Frayne J,
    2. Nicholson HD
    . Localization of oxytocin receptors in the human and macaque monkey male reproductive tracts: evidence for a physiological role of oxytocin in the male. Mol Hum Reprod 1998;4:527–32.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Zhong M,
    2. Boseman ML,
    3. Millena AC,
    4. Khan SA
    . Oxytocin induces the migration of prostate cancer cells: involvement of the Gi-coupled signaling pathway. Mol Cancer Res 2010;8:1164–72.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Baek KJ,
    2. Kwon NS,
    3. Lee HS,
    4. Kim MS,
    5. Muralidhar P,
    6. Im MJ
    . Oxytocin receptor couples to the 80 kDa Gh alpha family protein in human myometrium. Biochem J 1996;315(Pt 3):739–44.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Strakova Z,
    2. Soloff MS
    . Coupling of oxytocin receptor to G proteins in rat myometrium during labor: Gi receptor interaction. Am J Physiol 1997;272:E870–6.
    OpenUrlPubMed
  30. 30.↵
    1. Zhong M,
    2. Navratil AM,
    3. Clay C,
    4. Sanborn BM
    . Residues in the hydrophilic face of putative helix 8 of oxytocin receptor are important for receptor function. Biochemistry 2004;43:3490–8.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Monga M,
    2. Ku CY,
    3. Dodge K,
    4. Sanborn BM
    . Oxytocin-stimulated responses in a pregnant human immortalized myometrial cell line. Biol Reprod 1996;55:427–32.
    OpenUrlAbstract
  32. 32.↵
    1. Tomlins SA,
    2. Mehra R,
    3. Rhodes DR,
    4. Cao X,
    5. Wang L,
    6. Dhanasekaran SM,
    7. et al.
    Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007;39:41–51.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Reversi A,
    2. Rimoldi V,
    3. Marrocco T,
    4. Cassoni P,
    5. Bussolati G,
    6. Parenti M,
    7. et al.
    The oxytocin receptor antagonist atosiban inhibits cell growth via a “biased agonist” mechanism. J Biol Chem 2005;280:16311–8.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Busnelli M,
    2. Sauliere A,
    3. Manning M,
    4. Bouvier M,
    5. Gales C,
    6. Chini B
    . Functional selective oxytocin-derived agonists discriminate between individual G protein family subtypes. J Biol Chem 2012;287:3617–29.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Prieto Villapun JC,
    2. Solano Haro RM,
    3. Carmena Sierra MJ,
    4. Sanchez-Chapado M
    . [Importance of heterotrimeric G proteins in prostate cancer molecular biology]. Actas Urol Esp 2005;29:948–54.
    OpenUrlPubMed
  36. 36.↵
    1. Cao C,
    2. Huang X,
    3. Han Y,
    4. Wan Y,
    5. Birnbaumer L,
    6. Feng GS,
    7. et al.
    Galpha(i1) and Galpha(i3) are required for epidermal growth factor-mediated activation of the Akt- mTORC1 pathway. Sci Signal 2009;2:ra17.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    1. Ghosh P,
    2. Beas AO,
    3. Bornheimer SJ,
    4. Garcia-Marcos M,
    5. Forry EP,
    6. Johannson C,
    7. et al.
    A G{alpha}i-GIV molecular complex binds epidermal growth factor receptor and determines whether cells migrate or proliferate. Mol Biol Cell 2010;21:2338–54.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Molecular Cancer Research: 10 (10)
October 2012
Volume 10, Issue 10
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The Essential Role of Giα2 in Prostate Cancer Cell Migration
(Your Name) has forwarded a page to you from Molecular Cancer Research
(Your Name) thought you would be interested in this article in Molecular Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The Essential Role of Giα2 in Prostate Cancer Cell Migration
Miao Zhong, Shineka Clarke, BaoHan T. Vo and Shafiq A. Khan
Mol Cancer Res October 1 2012 (10) (10) 1380-1388; DOI: 10.1158/1541-7786.MCR-12-0219

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The Essential Role of Giα2 in Prostate Cancer Cell Migration
Miao Zhong, Shineka Clarke, BaoHan T. Vo and Shafiq A. Khan
Mol Cancer Res October 1 2012 (10) (10) 1380-1388; DOI: 10.1158/1541-7786.MCR-12-0219
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Wnt3 Promotes EMT and Acquired Resistance to Trastuzumab
  • Analysis of RAF-MEK-ERK Signaling in Pancreas Cancer
  • Patched Functions in Multidrug Transport
Show more Signaling and Regulation
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Rapid Impact Archive
  • Meeting Abstracts

Information for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCR

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Research
eISSN: 1557-3125
ISSN: 1541-7786

Advertisement